ScreenerHero

TRAW Traws Pharma, Inc.

NAS · US · Healthcare · Biotechnology · trawspharma.com
0.4790USD-7.88%Mkt Cap: 7.36M $P/E: —

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and CO…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.36M USD
Enterprise Value2.98M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)9.17M USD
Revenue/Share0.00 USD
Last Price0.4790 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.28
PEG—
EV/EBITDA-0.14
EV/Revenue—
P/SInfinity
P/B4.68
EPS (TTM)-1.64
EPS (Forward)-1.88
52W Range
0.43012% of range3.270
52W High3.270 USD
52W Low0.4301 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin328.67%
ROE-1457.87%
ROA86.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.18M USD
CapEx (TTM)2.58M USD
FCF Margin—
FCF Yield-181.03%
Net Debt-5.02M USD
Net Debt/EBITDA0.23
Balance Sheet
Debt/Equity—
Current Ratio0.93
Quick Ratio0.87
Book Value/Sh0.11 USD
Cash/Share0.33 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateSep 23, 2024
Analyst Consensus
Rating—
Target (Mean)1.000 USD
Upside (mean)+108.8%
Target Range1.000 USD – 1.000 USD
# Analysts1
Ownership
Shares Out.15.37M
Float11.94M
Insiders5.39%
Institutions40.06%
Short Interest
Short Ratio6.8d
Short % Float4.69%
Short % Out.3.98%
Shares Short612.22K
Short (prev mo.)623.76K
Technical
SMA 500.5424 (-11.7%)
SMA 2001.254 (-61.8%)
Beta1.53
S&P 52W Chg16.45%
Avg Vol (30d)1.05M
Avg Vol (10d)3.06M
Technical Indicators
RSI (14)39.3
MACD-0.0116
MACD Signal-0.0089
MACD Hist.-0.0027
BB Upper0.6144 USD
BB Middle0.5426 USD
BB Lower0.4708 USD
BB Width26.46%
ATR (14)0.0539 USD
Vol Ratio (20d)0.14x